Maternal and Infant Inflammatory Markers in Relation to Prenatal Arsenic Exposure in a U.S. Pregnancy Cohort

Shohreh F. Farzan1,*, Elizabeth B. Brickley2, Zhigang Li2, Diane Gilbert-Diamond2, Anal'a Gossai2, Yu Chen3, Caitlin G. Howe1, Thomas Palys2, and Margaret R. Karagas2

1Department of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA
2Children’s Environmental Health & Disease Prevention Research Center at Dartmouth, Hanover, NH, USA and Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA
3Department of Population Health, New York University School of Medicine, New York, NY, USA

Abstract

Introduction—Accumulating evidence indicates that arsenic (As), a potent environmental toxicant, may increase cardiovascular disease risk and adversely affect endothelial function at high levels of exposure. Pregnancy is a vulnerable time for both mother and child; however, studies examining the association between prenatal As exposure and plasma biomarkers of inflammation and endothelial function in mothers and newborns are lacking.

Methods—We examined maternal urinary As levels at gestational weeks 24 to 28 and levels of inflammatory biomarkers in plasma from 563 pregnant women and 500 infants’ cord blood. We assessed a multiplexed panel of circulating inflammatory and endothelial function markers, including tumor necrosis factor alpha (TNFα), monocyte chemoattractant protein 1 (MCP1), intercellular adhesion molecule (ICAM1) and vascular cell adhesion molecule (VCAM1).

Results—Compared with the bottom tertile, the highest tertile of maternal urinary As during pregnancy was associated with a 145.2 ng/mL (95% CI 4.1, 286.3; p=0.04) increase in cord blood ICAM1 and 557.3 ng/mL (95% CI −56.4, 1171.1; p=0.09) increase in cord blood VCAM1. Among mothers, the highest tertile of maternal urinary As during pregnancy was related to a 141.8 ng/mL (95% CI 26.1, 257.5; p=0.02) increase maternal plasma VCAM1 levels. Urinary As was unrelated to MCP1 or TNFα in maternal plasma and cord blood. In structural equation models, the
association between maternal urinary As and infant VCAM was mediated by maternal levels of VCAM ($\beta_{\text{mediation}}$: 0.024, 95% CI: 0.002, 0.050).

**Conclusion**—Our observations indicate that As exposure during pregnancy may affect markers of vascular health and endothelial function in both pregnant women and children, and suggest further investigation of the potential impacts on cardiovascular health in these susceptible populations.

**Keywords**
Arsenic; pregnancy cohort; New Hampshire; inflammatory markers; endothelial

**Introduction**

Arsenic (As) exposure continues to be a major public health concern across the globe. Worldwide, the main source of As exposure is contaminated groundwater, with an estimated 200 million individuals exposed to levels exceeding the World Health Organization safety standard and US EPA maximum contaminant level (MCL) of 10μg/L.\textsuperscript{1–3} In the US, nearly 44.5 million people rely on private wells as their primary water source and an estimated 7% of these systems exceed the As MCL.\textsuperscript{4–6} Furthermore, a growing number of studies have raised concerns about certain foods, including rice and rice products, as sources of As exposure.\textsuperscript{7–11}

Arsenic’s toxicity at high levels of exposure is well documented. Known primarily for its role as a potent carcinogen of the bladder, skin, kidney, liver and lung, As has also been associated with a multitude of adverse health effects, including respiratory disease, diabetes, neurological impairment, and immune dysfunction.\textsuperscript{3,4} Epidemiological evidence further supports a relationship between As exposure and cardiovascular effects and pregnant women and children may be especially vulnerable to these effects.\textsuperscript{12–18} We previously reported that women with higher urinary As levels during pregnancy had greater increases in blood pressure over the course of pregnancy.\textsuperscript{19} In children, early life As exposure has been associated with early indicators of cardiovascular risk, including increased blood pressure, as well as carotid intima media thickness (cIMT).\textsuperscript{20–22}

Arsenic-related cardiovascular dysfunction may occur by a number of pathways, such as increased inflammation, cytokine induction and production of reactive oxygen species, which can each affect endothelial activation and function.\textsuperscript{17,23} Cellular damage or toxic insults to the vascular endothelium activate a signaling cascade, triggering expression of pro-inflammatory mediator tumor necrosis factor alpha (TNFα). TNFα induces inflammatory responses by promoting secretion of cytokines and activating endothelial cells by promoting expression of adhesion molecules, such as intercellular adhesion molecule-1 (ICAM1) and vascular adhesion molecule-1 (VCAM1) on their surface.\textsuperscript{24,25} Adhesion molecules allow mononuclear cells to attach to the endothelium, a key step in atherosclerotic initiation. In experimental studies, As elevates circulating vascular inflammatory marker levels, including ICAM1 and VCAM1\textsuperscript{26–28}, increases monocyte adhesion to the vascular endothelium via increased binding to VCAM1\textsuperscript{28} and increases atherosclerotic lesion formation, along with expression of inflammatory mediators, such as monocyte chemoattractant protein 1 (MCP1),
at vascular lesion sites. Levels of these circulating markers may predict future cardiovascular disease risk, and of these, soluble VCAM1 and ICAM1 have been consistently related to chronic As exposure in studies among adults in Bangladesh.

However, very little is known about whether arsenic may affect these particular markers, which may indicate cardiovascular health, in either children or pregnant women. A recent study from an Iranian birth cohort found positive associations between ambient air pollutants and cord blood ICAM1, VCAM1 and endothelian-1, suggesting that these markers may be impacted by environmental exposures. We therefore hypothesized that As exposure may be associated with increases in plasma and cord blood levels of markers of endothelial dysfunction (VCAM1, ICAM1), and mediators of the endothelial inflammatory response (MCP1, TNFα) among mother-infant pairs enrolled in the New Hampshire Birth Cohort Study.

**Methods**

**The New Hampshire Birth Cohort**

The New Hampshire Birth Cohort is an ongoing study that began in January 2009, recruiting 18–45 year old pregnant women receiving prenatal care at study clinics, as previously described. Women were enrolled at 24–28 weeks gestation if they reported using water from a private well at their residence since their last menstrual period and were not planning to move prior to delivery. Only singleton births were included in the study. All protocols were approved by the Dartmouth College Institutional Review Boards. Participants provided written, informed consent upon enrollment.

**Medical Record Review**

Participants completed a detailed medical history and lifestyle questionnaire upon enrollment, which ascertained sociodemographic factors (age, race/ethnicity, marital status, education), reproductive history (previous pregnancies, complications, birth outcomes), and health history. Women were asked about habits, including tobacco and alcohol use, along with their home water source and consumption. At two weeks postpartum, mothers were sent a follow-up questionnaire to obtain additional information about pregnancy, delivery and changes in key exposures. Participants also consented to a medical record review, which allowed additional information to be recorded about prenatal infections, medication use, birth outcomes and delivery details, and general health of the women and their infants after birth.

**Arsenic Exposure Assessment**

Women provided a spot urine sample upon enrollment at 24–28 weeks gestation, which was collected and stored, as previously described. Urine samples were analyzed for levels of arsenite (iAs\(^{III}\)), arsenate (iAs\(^{V}\)), monomethylarsonic acid (MMA), dimethylarsinic acid (DMA) and arsenobetaine by high-performance liquid chromatography (HPLC) inductively coupled plasma mass spectrometry (ICP-MS) at the University of Arizona Hazard Identification Core. Total urinary As was calculated by summing inorganic (iAs = iAs\(^{III}\)+iAs\(^{V}\)) and organic (DMA, MMA) metabolites. Arsenobetaine, a form of As found in
fish and seafood was excluded, as it is thought to pass through the body unmetabolized.\textsuperscript{40} Urine samples that registered below the As detection limit (ranging from 0.10–0.15 μg/L for individual urine species; 14.0%, 20.8%, and 40.3% of the study population were below the detection limit for DMA, MMA and iAs, respectively) were assigned a value equal to the detection limit divided by the square root of two. Participants were given instructions and prepaid mailing materials upon enrollment to collect samples of their home tap water and return the samples to the study office, which were analyzed by high resolution inductively coupled plasma mass spectrometry (ICP-MS) at the Dartmouth Trace Element Analysis Core, as previously described.\textsuperscript{9} Water arsenic detection limits ranged from 0.005–0.074 μg/L.

**Plasma and cord blood inflammatory markers testing**

We selected the first 564 mothers with adequate plasma sample volumes for testing and an available maternal urine sample for As assessment. A paired infant cord blood sample was available for 500 women. A total of 563 mothers and 500 infants were successfully assayed for one or more markers.

Maternal and infant circulating protein marker levels were measured using MILLIPLEX-MAP human magnetic bead multiplexed panels (Millipore, Billerica, MA), according to manufacturers instructions. MCP1 and TNFα were assayed using undiluted plasma samples and had minimum assay sensitivities of 1.9 and 0.7 pg/ml for MCP1 and TNFα, respectively. Plasma samples assayed for soluble ICAM1 and VCAM1 were diluted 1:100 and had minimum assay sensitivities of 0.019 and 0.024 ng/ml for ICAM1 and VCAM1, respectively. Calibration curves of recombinant standards were prepared with three-fold dilution steps in the same matrix as the samples. Standards were measured in triplicate, samples were measured once, and blank values were subtracted from all readings. All assays were carried out directly in a 96-well filtration plate (Millipore) at room temperature and protected from light. Briefly, wells were pre-wet with 100 μl PBS containing 1% BSA. Then, 100 μl volume of beads and either a standard, sample, spikes, or blank were added and incubated at room temperature for 30 min with continuous shaking. Beads were washed with 100 μl PBS containing 1% BSA and 0.05% Tween 20. A cocktail of biotinylated antibodies (50 μl/well) was added to beads for a further 30 min incubation with continuous shaking. Beads were washed, then streptavidin-phycoerythrin was added for 10 min. Beads were again washed and resuspended in 125 μl of PBS containing 1% BSA and 0.05% Tween 20. The fluorescence intensity of the beads was measured using a Bio-Plex Array Reader (Bio-Rad Laboratories, Hercules, CA) and analyzed using Bio-Plex Manager software with five-parametric curve fitting. Markers below the detection limit were assigned a value equal to the detection limit divided by the square root of two.

Maternal and infant samples were randomized across plates. Assays were performed in three separate runs and batch assignment was included in models as a covariate to control for batch-to-batch variability. Approximately 10% of sample wells on each plate were reserved for quality control samples. Replicates of four different non-study plasma samples were included on each plate to account for inter- and intra-plate variability, for which coefficients of variation for these six markers ranged from 9–20% and 3–19%, respectively. All assays
were within the range of acceptable variability according to the manufacturer’s standards and generally acceptable in epidemiological biomarker studies. In addition to controlling for batch effects within our models, we also evaluated whether there were differences in exposure between plates and batches by examining the mean arsenic exposure by group. We tested this using analysis of variance tests run with SAS PROC GLM and in both cases, we did not find any statistically significant differences between groups by plate (F = 1.11, \( p=0.35 \)) or by batch (\( F=2.25, \ p=0.11 \)).

**Statistical Analysis**

Characteristics of the study sample and the overall cohort were assessed and frequencies and/or means were compared by chi-squared or one-way ANOVA tests. We computed Spearman’s rank correlations between maternal and infant biomarkers. To assess the shape of the correlations, the median and interquartile ranges of each inflammatory marker on the y-axes were plotted against the median for each tertile of maternal urinary arsenic on the x-axes. Using total urinary As during pregnancy (as a continuous measure and/or categorized by tertiles of exposure) as our measure of exposure for both mothers and infants, we tested for associations with maternal and infant inflammatory markers, using linear regression models, adjusted for potential confounders. These included factors that could potentially influence inflammation or vascular function based on *a priori* considerations, although they may not be related to As exposure. Final models included age at enrollment, smoking and/or secondhand smoke exposure during pregnancy, education, urinary creatinine and batch assignment. P-values for trends were estimated using urinary As tertiles and statistical significance was determined at \( p<0.05 \).

We also considered the possibility of effect modification by pre-pregnancy body mass index (BMI), maternal weight gain, and infant birth size, which were evaluated by inspection of stratum specific estimates and by including a multiplicative interaction term in the multivariable logistic regression models and assessing its statistical significance at \( p<0.05 \) using likelihood ratio chi-square tests. In stratified analyses, maternal pre-pregnancy BMI was categorized by World Health Organization standards (i.e. <25 kg/m\(^2\): underweight to normal; 25 to 30 kg/m\(^2\): overweight; \( \geq 30 \) kg/m\(^2\): obese). Maternal weight gain was categorized as normal versus excessive based on IOM standards, based on pre-pregnancy BMI. Infant birth size categories were based on gestational age and sex, using methods described by Fenton et al. A structural equation model (SEM) was applied to simultaneously estimate the direct (maternal urinary As on infant cord blood levels of VCAM and ICAM) and the indirect pathways (with plasma levels of maternal VCAM or ICAM during pregnancy as mediators). This analysis is an extension of multivariable regression analysis that permits the simultaneous modeling of multiple dependent variables to assess potential causal effects among the dependent variables while adjusting for the aforementioned covariates in the regression analysis. The SEM analysis was done in the software Mplus 7.11. Generalized additive models (GAM), adjusted for all aforementioned covariates, with cubic regression splines were used to generate figures in R software.
Results

A total of 563 mothers and 500 paired infants from the NHBCS were included in this analysis. Nearly 1 in every 7 households (58 of 414 available samples; 14%) tested in this study sample had water As levels above EPA MCL of 10μg/L, with a mean As level of 4.7 μg/L (range: 0.003–147.7 μg/L) (Table 1). The mean values for water As were similar to the values observed in the overall cohort, but a slightly higher proportion of women in this sample (14.0%) had water levels exceeding the MCL than the overall cohort (11.5%) (p = 0.045). Women in this sample had a mean urinary As concentration of 5.8 μg/L with values ranging from 0.2–288.5 μg/L, which were very similar to the values observed in the overall cohort and not significantly different (Table 1). No other statistically significant differences were observed between the study population and the overall cohort.

We examined correlations between maternal and infant levels of the markers that we investigated. The maternal and infant levels were moderately correlated with the strongest positive correlation observed for maternal ICAM with infant ICAM (\(\rho=0.76\)) (Figure 1). Maternal ICAM also was positively correlated with infant VCAM (\(\rho=0.58\)) (Figure 1). Maternal VCAM was positively correlated with infant VCAM (\(\rho=0.56\)), and infant ICAM (\(\rho=0.60\)) (Figure 1). Maternal TNFα was positively correlated with infant VCAM (\(\rho=0.50\)) and infant ICAM (\(\rho=0.43\)) (Figure 1).

Using linear regression models, adjusted for covariates, we observed that compared with the lowest As exposure tertile, the highest tertile of maternal urinary As during pregnancy was positively related to cord blood levels of ICAM1 (ng/ml) (\(\beta_{Tert3}: 145.2, 95\% CI: 4.1, 286.3; \ p\)-trend= 0.04) (Table 2). We observed a similar positive trend when we examined the dose-response relationship between maternal urinary As and infant ICAM1, using adjusted generalized additive models with cubic regression splines (Figure 2a). We also observed marginally significant increases in cord blood VCAM levels (ng/ml) among infants born to mothers within the higher tertiles of urinary As (\(\beta_{Tert2}: 532.8, 95\% CI: −56.9, 1122.5; \beta_{Tert3}: 557.3, 95\% CI: −56.4, 1171.1; \ p\)-trend= 0.09), as compared to the level in those born to mothers within the lowest tertile although the trend did not reach statistical significance (Table 2).

Among mothers, the higher tertiles of maternal urinary As during pregnancy were positively related to maternal plasma levels of VCAM1 (ng/ml) (\(\beta_{Tert2}: 97.3, 95\% CI: −11.7, 206.3; \beta_{Tert3}: 141.8, 95\% CI: 26.1, 257.5; \ p\)-trend= 0.02), as compared to the lowest tertile (Table 3). We observed a similar positive trend when we examined the dose-response relationship between maternal urinary As and maternal VCAM1 using adjusted generalized additive models with cubic regression splines (Figure 2b). Further, the highest tertile of maternal urinary As during pregnancy was positively related to maternal plasma levels of MCP1 (pg/ml) (\(\beta_{Tert3}: 10.4; 95\% CI: −1.5, 22.3; \ p\)-trend= 0.09), as compared to the lowest tertile, although the trend did not reach statistical significance.

We tested for effect modification by infant sex, birth size, maternal BMI and maternal weight gain in stratified models. However, the relation between urinary As and infant cord
blood markers did not appreciably vary by infant sex or infant birth size, nor did we observe differences by maternal BMI and maternal weight gain of associations (data not shown).

Given that some studies have suggested that seafood and fish consumption may influence the level of organic As species in urine samples, we performed a sensitivity analysis to explore the impact of seafood consumption on our results. Exclusion of seafood-consumers reduced our sample size to 475 mothers and 426 infants. We found that our results were robust, even when we excluded those individuals who reported consuming fish or seafood within the three days prior to urine collection. Among those mothers who reported that they did not eat seafood within the three days prior to urine collection, maternal urinary arsenic remained positively associated with VCAM1 ($B_{\text{tert2}}$: 113.4, 95% CI: $-7.2$, 234.0; $B_{\text{tert3}}$: 180.0, 95% CI: $51.1$, 309.0; p-trend=0.01). Among infants born to mothers who reported that they did not eat seafood within the three days prior to urine collection, the positive association between maternal urinary arsenic and VCAM1 was marginally improved ($B_{\text{tert2}}$: 674.9, 95% CI: $-22.0$, 1352.1; $B_{\text{tert3}}$: 814.1, 95% CI: 93.0, 1535.1; p-trend=0.03) and remained similar with ICAM1 ($B_{\text{tert2}}$: 100.6, 95% CI: $-55.0$, 256.2; $B_{\text{tert3}}$: 174.3, 95% CI: 8.6, 340.0; p-trend=0.04).

Lastly, we built a structural equation model to investigate how maternal VCAM and ICAM plasma levels may contribute to the effect of maternal urinary As on infant cord blood levels of VCAM and ICAM. We modeled VCAM and ICAM independently, adjusted for covariates. According to the model estimates, maternal urinary As was associated with increased maternal VCAM levels ($\beta$= 0.024, 95% CI: 0.002, 0.05) which in turn were related to increased infant VCAM levels ($\beta$= 0.52, 95% CI: 0.41, 0.63) (Supplementary Figure 1). For VCAM, the overall mediational effect was statistically significant ($\beta$= 0.024, 95% CI: 0.002, 0.05). We did not observe a statistically significant mediational effect in our model of maternal urinary As with maternal and infant ICAM, but we observed a similar trend, indicating that increases in maternal ICAM may mediate the effect on infant ICAM levels ($\beta$= 0.16, 95% CI: 0.09, 0.24) (Supplementary Figure 1).

**Discussion**

In this cohort study of US women and their newborns, we evaluated the associations between prenatal As exposure and circulating levels of maternal plasma and infant cord blood levels of markers of inflammation. We observed a positive association between maternal pregnancy urinary As and infant cord blood levels of ICAM and a similar, albeit weaker positive association with cord blood levels of VCAM. We also found a relationship between maternal urinary As and maternal plasma levels of VCAM, as well as an association with levels of MCP1 of borderline statistical significance. Subsequent investigation of maternal VCAM and ICAM as mediators of As-related effects on infant VCAM and ICAM suggested that As may impact markers of infant endothelial function via modulation of maternal markers. Although the overall levels of arsenic exposure in our study population are relatively lower than other areas of the world (<50μg/L in well water), our results are consistent with previous epidemiological studies in Bangladesh among adults with much higher levels of As exposure that have found that As increases circulating plasma levels of soluble VCAM1 and ICAM1.34,35 These results indicate that maternal As exposure...
at relatively low levels during pregnancy may have an effect on inflammatory pathways
and/or endothelial function in both the mother and her child.

To our knowledge, no other epidemiological studies have examined the association between
As exposure during pregnancy and levels of endothelial function markers in both pregnant
women and their infants. A number of studies have observed relationships between maternal
As exposure and alterations in expression of markers of immune function, including
inflammatory cytokines, and glucocorticoid and TNF signaling pathways. However, existing studies of endothelial function markers in this vulnerable population have been
generally limited to investigations of these biomarkers in relation to pregnancy complications. During pregnancy, women may experience improved endothelial
function, a cardiovascular adaption to support the growing fetus. This pregnancy-associated improvement in endothelial response could potentially blunt the effects of
environmental insults on the endothelium. However, in our study we observed a positive
association between urinary As and maternal plasma marker VCAM and a possible positive
association with MCP1, which have been related to inflammation and endothelial
dysfunction. This could signal greater cardiovascular risks for more highly As exposed
women later in life, as these markers have been associated with cardiovascular risk in
adults. For example, one study found that the highest quartile of baseline ICAM1 (>260
ng/mL) was associated with an increased risk of myocardial infarction (RR: 1.6, 95% CI
1.1–2.4), while another group observed a 2.1 fold (95% CI: 1.1, 4.0) greater risk of death
among coronary artery disease patients within the top quartile of baseline VCAM1
concentrations compared with lower quartiles. Recent work has indicated that women
who experience cardiovascular complications or hypertensive disorders in pregnancy are at
sharply increased risks of cardiomyopathy, acute myocardial infarction, stroke, or new-onset
heart failure beginning within just a few years of giving birth. Altered vascular function
also may increase the risk of adverse pregnancy outcomes and placental insufficiency.
Increased maternal plasma levels of endothelial markers during pregnancy, including
VCAM1 and ICAM1, have been implicated in the development of pre-eclampsia, fetal
endothelial function and increased risk of preterm delivery and lower birth weight. Some have speculated that As’s vascular impacts could affect the placenta by leading to
placental insufficiency and intrauterine growth retardation, thus potentially underlying As-
related effects on fetal growth and birth weight. While it is unclear whether As-related
changes in a mother’s vascular health may affect her child’s health, our structural equation
models suggest that As’s effects on biomarkers of maternal endothelial function may in turn
mediate similar changes in these same biomarkers in infants. Nonetheless, the long-term
impacts of these changes have yet to be explored.

Our work indicates that prenatal As exposure may be related to elevated levels of
inflammatory markers in infants. Our findings are similar to a recent study from a birth
cohort in Iran, which found associations between prenatal exposure to ambient air pollution
and elevated VCAM1, ICAM1 and endothelian-1 levels in cord blood. Additional studies
are needed to determine whether these higher marker levels in early life may be related to
any long-term health impacts. Although clinical symptoms of cardiovascular dysfunction
occur much later in life, there is clear evidence that atherogenesis is a lifelong process and
vascular changes can begin very early in childhood. While speculative, these
inflammatory markers are hypothesized to play a role in the early phases of disease based on their role in CVD in adults and several studies have demonstrated that children at higher cardiovascular risk due to obesity, dyslipidemia, or hypertension have higher observed levels of VCAM1, ICAM1, and MCP1 as compared to healthy children. Nevertheless, growing evidence supports a role for As in the promotion of adult cardiovascular disease and studies prospectively examining the effects of early life As exposure on cardiovascular function in children have found associations between in utero and early life As exposure to increased blood pressure, carotid intima media thickness (cIMT) and biomarkers of oxidative stress. While these inflammatory markers may be related to other chronic disease pathways and have yet to be fully explored in early life, our results are in line with previous studies that have suggested that early life As exposure in children may alter early biomarkers and preclinical indicators of cardiovascular function.

The strengths of our study include a relatively large sample of mother and infant pairs, with a range of As exposure levels, and rich covariate information collected from medical records and questionnaires. Our results are consistent with previous studies in adults that have observed similar associations between As exposure and endothelial function exposed to higher concentrations of water As. Unlike previous studies that have observed relationships between As exposure and pro-inflammatory cytokines, we did not see an association between As exposure and TNFα. This could suggest that the lower levels of As exposure in our population have more targeted effects on endothelial function and may not have broader effects on systemic inflammation. It is likely that other key pathways may be impacted by As exposure that we have not investigated in this study, thus a wider range of markers of inflammation and endothelial function should be explored in future studies to more fully elucidate the cardiovascular effects of As. A potential limitation of this study is that, to our knowledge, these markers have not been validated in cord blood using this multiplexed platform. However, another study has recently assessed these markers in the context of air pollution using enzyme-linked immune-sorbent assays (ELISA) and reported concentrations of VCAM1 and ICAM1 in cord blood within a similar range as our study. Lastly, our study population of women is relatively well educated and primarily white, which may underrepresent different racial or socioeconomic groups, limiting the generalizability of our results.

In conclusion, we found that As exposure during pregnancy was associated with increases in markers of endothelial function in a US population of mothers. Our results further suggest that As’s effects on markers of infant endothelial function may be mediated by impacts on maternal levels of these markers. Whether these effects are associated with long-term adverse cardiovascular health consequences will need to be assessed in future studies.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

**Funding sources and ethical considerations**
S.F. Farzan is supported by a NIEHS K99/R00 (R00ES024144). Funding for this study was provided by the NIEHS Superfund Research Program (P42ES007373) and the Children’s Center for Environmental Health and Disease Prevention Research (NIEHS and USEPA grants ES022832 and RD83459901). The funding agencies that supported this work had no role in the planning, design, or execution of this study, nor any role in data analysis or manuscript preparation.

References


Highlights
Arsenic (As) exposure has been associated with elevated cardiovascular disease risk
Plasma inflammatory and endothelial function markers may indicate future CVD risks
Studies of As exposure and maternal-infant inflammatory markers are lacking
Increased As was associated with greater maternal VCAM and infant ICAM Prenatal As exposure may increase endothelial dysfunction in mothers and infants
Figure 1.
Maternal plasma and infant cord blood marker correlation coefficients. Correlations were examined using Spearman’s rank correlation coefficients. Positive correlations are shown in blue, negative correlations are shown in red, with darker shades indicating stronger correlations. An asterisk (*) indicates statistically significant correlations ($p < 0.05$).
Figure 2.
Associations between maternal urinary arsenic and A) infant cord blood ICAM1 and B) maternal plasma VCAM1, as modeled using generalized additive models with cubic regression splines, adjusted for
Table 1

Selected characteristics for mothers (n=563) and paired infants (n=500) participating in the New Hampshire Birth Cohort Study.

<table>
<thead>
<tr>
<th>Maternal Variables</th>
<th>% or mean (SD)</th>
<th>Overall cohort (n=1033)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age at enrollment</td>
<td>31.2 (4.8)</td>
<td>31.06 (4.9)</td>
</tr>
<tr>
<td>Race, white</td>
<td>98.1%</td>
<td>98.5%</td>
</tr>
<tr>
<td>Educational attainment *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than college</td>
<td>34.4%</td>
<td>32.9%</td>
</tr>
<tr>
<td>College graduate</td>
<td>39.8%</td>
<td>39.7%</td>
</tr>
<tr>
<td>Any post-graduate schooling</td>
<td>25.8%</td>
<td>27.5%</td>
</tr>
<tr>
<td>Relationship status *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>87.1%</td>
<td>86.3%</td>
</tr>
<tr>
<td>Single, separated or divorced</td>
<td>12.9%</td>
<td>13.7%</td>
</tr>
<tr>
<td>Pre-pregnancy BMI *</td>
<td>26.0 (5.7)</td>
<td>26.1 (5.9)</td>
</tr>
<tr>
<td>Weight gain during pregnancy *</td>
<td>35.6 (14.7)</td>
<td>34.7 (14.9)</td>
</tr>
<tr>
<td>Parity *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nulliparous</td>
<td>40.0%</td>
<td>40.0%</td>
</tr>
<tr>
<td>1 to 2</td>
<td>51.2%</td>
<td>51.7%</td>
</tr>
<tr>
<td>3+</td>
<td>8.8%</td>
<td>8.3%</td>
</tr>
<tr>
<td>Ever smoked during pregnancy *</td>
<td>5.9%</td>
<td>6.4%</td>
</tr>
<tr>
<td>Exposed to secondhand smoke during pregnancy *</td>
<td>12.3%</td>
<td>13.4%</td>
</tr>
<tr>
<td>Well water arsenic (μg/L) *</td>
<td>4.72 (12.22); range 0.003–147.74</td>
<td>4.46 (13.37); range 0.002–189.34</td>
</tr>
<tr>
<td>Well water arsenic above the 10μg/L MCL</td>
<td>14.0% #</td>
<td>11.5%</td>
</tr>
<tr>
<td>Urinary arsenic (μg/L)</td>
<td>5.78 (13.34); range 0.21–288.48</td>
<td>6.05 (13.19); range 0.21–288.48</td>
</tr>
<tr>
<td>Toenail arsenic (μg/g) *</td>
<td>0.08 (0.08); range 0.001–0.70</td>
<td>0.08 (0.08); range 0.001–0.70</td>
</tr>
</tbody>
</table>

Infant Variables

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male</td>
<td>48.8%</td>
<td>48.9%</td>
</tr>
<tr>
<td>Birth Weight, grams *</td>
<td>3486.9 (490.7)</td>
<td>3458.0 (519.6)</td>
</tr>
<tr>
<td>Gestational age, weeks</td>
<td>39.6 (1.3)</td>
<td>39.3 (1.9)</td>
</tr>
</tbody>
</table>

* Missing (n) in study sample: pre-pregnancy BMI (11); pregnancy weight gain (19); relationship status (39); education level (39); parity (2); smoking/secondhand smoke exposure during pregnancy (38); water arsenic (145); toenail arsenic (127); birth weight (6).

# Frequencies and means were compared by chi-squared or one-way ANOVA tests, respectively and statistically significant differences (p<0.05) are marked.
Table 2
Linear regression models of maternal urinary As by tertiles and inflammatory markers in infant cord blood.

<table>
<thead>
<tr>
<th>Infant Marker</th>
<th>N</th>
<th>β (95% CI)</th>
<th>p-trend</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VCAM1</strong> (ng/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As Tertile 1 (0.20–2.38 μg/L)</td>
<td>173</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>As Tertile 2 (2.38–5.30 μg/L)</td>
<td>160</td>
<td>532.8 (−56.9, 1122.5)</td>
<td>*</td>
</tr>
<tr>
<td>As Tertile 3 (5.30–288.5 μg/L)</td>
<td>167</td>
<td>557.3 (−56.4, 1171.1)</td>
<td>*</td>
</tr>
<tr>
<td><strong>ICAM1</strong> (ng/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As Tertile 1 (0.20–2.38 μg/L)</td>
<td>173</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>As Tertile 2 (2.38–5.30 μg/L)</td>
<td>160</td>
<td>74.8 (−60.8, 210.3)</td>
<td></td>
</tr>
<tr>
<td>As Tertile 3 (5.30–288.5 μg/L)</td>
<td>167</td>
<td>145.2 (4.1, 286.3)</td>
<td>**</td>
</tr>
<tr>
<td><strong>MCP1</strong> (pg/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As Tertile 1 (0.20–2.38 μg/L)</td>
<td>173</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>As Tertile 2 (2.38–5.30 μg/L)</td>
<td>160</td>
<td>33.8 (−22.7, 90.3)</td>
<td></td>
</tr>
<tr>
<td>As Tertile 3 (5.30–288.5 μg/L)</td>
<td>167</td>
<td>6.5 (−52.3, 65.4)</td>
<td>0.89</td>
</tr>
<tr>
<td><strong>TNFα</strong> (pg/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As Tertile 1 (0.20–2.38 μg/L)</td>
<td>173</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>As Tertile 2 (2.38–5.30 μg/L)</td>
<td>160</td>
<td>0.16 (−0.6, 0.9)</td>
<td></td>
</tr>
<tr>
<td>As Tertile 3 (5.30–288.5 μg/L)</td>
<td>167</td>
<td>0.36 (−0.4, 1.1)</td>
<td>0.35</td>
</tr>
</tbody>
</table>

* 0.1 > p > 0.05;  
** p < 0.05

Adjusted for enrollment age, education, maternal smoking, secondhand smoke exposure, urinary creatinine, and batch assignment.
Table 3
Linear regression models of maternal urinary As by tertiles and inflammatory markers in maternal plasma.

<table>
<thead>
<tr>
<th>Maternal Marker</th>
<th>N</th>
<th>$\beta$ (95% CI)</th>
<th>p-trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>VCAM1 (ng/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As Tertile 1 (0.20–2.38μg/L)</td>
<td>197</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>As Tertile 2 (2.38–5.30μg/L)</td>
<td>183</td>
<td>97.3 (−11.7, 206.3)</td>
<td>* 0.02</td>
</tr>
<tr>
<td>As Tertile 3 (5.30–288.5 μg/L)</td>
<td>183</td>
<td>141.8 (26.1, 257.5)</td>
<td>**</td>
</tr>
<tr>
<td>ICAM1 (ng/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As Tertile 1 (0.20–2.38μg/L)</td>
<td>197</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>As Tertile 2 (2.38–5.30μg/L)</td>
<td>183</td>
<td>86.9 (−179.6, 353.4)</td>
<td></td>
</tr>
<tr>
<td>As Tertile 3 (5.30–288.5 μg/L)</td>
<td>183</td>
<td>−3.9 (−286.7, 279.0)</td>
<td>0.98</td>
</tr>
<tr>
<td>MCP1 (pg/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As Tertile 1 (0.20–2.38μg/L)</td>
<td>197</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>As Tertile 2 (2.38–5.30μg/L)</td>
<td>183</td>
<td>8.0 (−3.2, 19.2)</td>
<td></td>
</tr>
<tr>
<td>As Tertile 3 (5.30–288.5 μg/L)</td>
<td>183</td>
<td>10.4 (−1.5, 22.3)</td>
<td>* 0.09</td>
</tr>
<tr>
<td>TNFα (pg/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As Tertile 1 (0.20–2.38μg/L)</td>
<td>197</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>As Tertile 2 (2.38–5.30μg/L)</td>
<td>183</td>
<td>0.13 (−0.30, 0.56)</td>
<td></td>
</tr>
<tr>
<td>As Tertile 3 (5.30–288.5 μg/L)</td>
<td>183</td>
<td>0.39 (−0.07, 0.84)</td>
<td>* 0.12</td>
</tr>
</tbody>
</table>

* 0.1>p>0.05;  
** p<0.05

Adjusted for enrollment age, education, maternal smoking, secondhand smoke exposure, urinary creatinine, and batch assignment.